Nasdaq

IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist

POTOMAC, Md.--(BUSINESS WIRE)-- IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced that the Company's proprietary molecule, IGC-1A, has been identified as a ...
Business Wire

Radella Pharmaceuticals Announces Topline Data from the Phase 1a Study of MD-18, a First-In-Class Peptide Targeting PTP1B for Obesity

NEW YORK--(BUSINESS WIRE)--Radella Pharmaceuticals, LLC., a clinical-stage biopharmaceutical company developing innovative therapies for cardiometabolic disorders, today announced topline results from ...
Pharmabiz

Zealand Pharma announces positive phase 1a top-line results with Kv1.3 channel blocker ZP9830

Zealand Pharma A/S, a biotechnology company transforming the future of metabolic health, has announced positive phase 1a single ascending dose (SAD) topline results for the company’s Kv1.3 channel ...
Morningstar

Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects

Metabolics Pharma (“Metabolics”), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced top-line data from a ...